Patent · US Active

PACA and cabazitaxel for anti-cancer treatment

US11806330B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignees

SINTEFF TTO AS · NO
OSLO UNIVERSITETSSYKEHUS · NO

Inventors

Yrr Morch · Trondheim, NO
Einar Sulheim · Trondheim, NO
Kjersti Flatmark · Oslo, NO
Karianne Giller Fleten · Oslo, NO
Per Stenstad · Trondheim, NO
Heidi Johnsen · Trondheim, NO
Ruth Schmid · Trondheim, NO

Key dates

Filing date	Mar 27, 2019
Grant date	Nov 7, 2023
Priority date	—
Expiry date	Mar 27, 2039

Classification

Technology area (CPC B)Performing Operations; Transporting
CPC primaryB82Y5/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.